You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
|
|---|---|
| Published in |
Lancet Infectious Diseases, May 2012
|
| DOI | 10.1016/s1473-3099(12)70087-7 |
| Pubmed ID | |
| Authors |
Peter C Richmond, Helen S Marshall, Michael D Nissen, Qin Jiang, Kathrin U Jansen, Maria Garcés-Sánchez, Federico Martinón-Torres, Johannes Beeslaar, Leszek Szenborn, Jacek Wysocki, Joseph Eiden, Shannon L Harris, Thomas R Jones, John L Perez, on behalf of the 2001 Study Investigators |
| Abstract |
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent recombinant factor H-binding protein vaccine (recombinant lipoprotein 2086) has been developed to provide broad coverage against diverse invasive meningococcus serogroup B strains. Our aim was to test the immune response of this vaccine. |
X Demographics
The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 12% |
| United Kingdom | 4 | 12% |
| Mexico | 3 | 9% |
| France | 2 | 6% |
| Netherlands | 1 | 3% |
| Australia | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 18 | 53% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 30 | 88% |
| Practitioners (doctors, other healthcare professionals) | 4 | 12% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| United States | 1 | <1% |
| Kenya | 1 | <1% |
| Unknown | 108 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 13% |
| Student > Bachelor | 14 | 13% |
| Researcher | 13 | 12% |
| Other | 11 | 10% |
| Student > Master | 7 | 6% |
| Other | 20 | 18% |
| Unknown | 32 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 32% |
| Agricultural and Biological Sciences | 11 | 10% |
| Nursing and Health Professions | 6 | 5% |
| Immunology and Microbiology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 12 | 11% |
| Unknown | 39 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2023.
All research outputs
#974,999
of 25,371,288 outputs
Outputs from Lancet Infectious Diseases
#1,339
of 6,037 outputs
Outputs of similar age
#4,883
of 176,343 outputs
Outputs of similar age from Lancet Infectious Diseases
#2
of 49 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,037 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 92.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,343 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.